Compare STKS & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STKS | BYSI |
|---|---|---|
| Founded | 2004 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.4M | 58.4M |
| IPO Year | 2011 | 2016 |
| Metric | STKS | BYSI |
|---|---|---|
| Price | $1.85 | $1.67 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.70 | N/A |
| AVG Volume (30 Days) | ★ 20.1K | 19.4K |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $805,722,000.00 | N/A |
| Revenue This Year | $7.47 | N/A |
| Revenue Next Year | $8.12 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 19.66 | N/A |
| 52 Week Low | $1.65 | $1.18 |
| 52 Week High | $4.67 | $2.44 |
| Indicator | STKS | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 47.34 | 47.43 |
| Support Level | $1.70 | $1.55 |
| Resistance Level | $2.06 | $1.83 |
| Average True Range (ATR) | 0.12 | 0.11 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 20.95 | 26.32 |
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through three segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.